IBRX - Company ID 0001326110
The table below shows ImmunityBio, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $113.29M | $14.74M | $622.00K | $240.00K | $934.00K | $605.00K |
| Cost of revenue | $753.00K | $0.00 | $0.00 | $0.00 | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | $190.14M | $232.37M | $248.15M | $195.96M | $139.51M |
| SG&A |
ImmunityBio, Inc. reported annual revenue of $113.29M for fiscal year 2025. That is up 668.3% from $14.74M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $44.00K (FY 2016) to $113.29M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| $168.78M |
| $129.62M |
| $102.71M |
| $135.26M |
| $71.32M |
| Operating income | -$256.03M | -$344.18M | -$362.25M | -$351.30M | -$330.28M | -$220.88M |
| Income tax | -$135.00K | $0.00 | -$40.00K | $34.00K | $9.00K | -$1.85M |
| Net income | -$351.50M | -$413.60M | -$583.90M | -$417.30M | -$349.80M | -$221.85M |
| EPS (diluted) | -$0.38 | -$0.62 | -$1.15 | -$1.04 | -$0.89 | -$0.59 |